These include cytokine release syndrome, hematologic and neurologic toxicity, and the risk of infection.[20] An antibody fusion protein drug comprising two interferon α2β molecules fused to an anti‐CD38 mAb (modakafusp alfa/TAK‐573) in phase 1/2 studies remains to be fully evaluated for safety and tolerability in patients with MM and relapsed/refractory MM (https://clinicaltrials.gov/). This evidence concerns the gene CD38 and Miyoshi myopathy.